To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer

Required: EGFR wild-type

Subjects are known to have genetic abnormalities that have been approved for targeted drug therapy (non-squamous cell carcinoma subjects are required to have EGFR or ALK gene tested or provide previous test reports during the screening period)

Required: ALK wild-type

Subjects are known to have genetic abnormalities that have been approved for targeted drug therapy (non-squamous cell carcinoma subjects are required to have EGFR or ALK gene tested or provide previous test reports during the screening period)

Must have received: anti-PD-1 therapy — neoadjuvant

previously received PD-1/PD-L1 inhibitors combined with chemotherapy neoadjuvant therapy

Must have received: anti-PD-L1 therapy — neoadjuvant

previously received PD-1/PD-L1 inhibitors combined with chemotherapy neoadjuvant therapy

Must have received: chemotherapy — neoadjuvant

previously received PD-1/PD-L1 inhibitors combined with chemotherapy neoadjuvant therapy

Must have received: surgery — definitive (R0 resection)

underwent R0 resection for curative purposes before surgery

Cannot have received: Chinese patent medicines with anti-tumor indications (compound Cantharides capsule, Kangai injection, Kanglaite capsule/injection, Aidi injection, Bruceae oil injection/capsule, Xiaoaipingtablet/injection, hualbufatin capsule)

Within 2 weeks before starting the administration, it has been treated with Chinese patent medicines (including compound Cantharides capsule, Kangai injection, Kanglaite capsule/injection, Aidi injection, Bruceae oil injection/capsule, Xiaoaipingtablet/injection, hualbufatin capsule, etc.) with anti-tumor indications specified in the NMPA approved drug instructions